Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — Investor Presentation (June 2021)
19 slides from Stablecoin Development's investor presentation, June 2021
Slide 1: NovaBay Investor Presentation June 2021
N“vaBay Investor Presentation PHARMA June 2021 NYSE American: NBY www.Novabay.com www.Avenova.com www.Cellerx.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements co a Tid r x > a This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “antici
Slide 3: NovaBay Overview
NovaBay Overview * Established Avenova® as the No. 1 antimicrobial lid and lash spray in the U.S. dry eye market ¢ Multi-pronged commercial distribution strategy ¢« 20mL available direct-to-consumer without a prescription * Online channels like Amazon.com, Walmart.com, CVS.com, and Avenova.com * CVS
Slide 4: Investment Highlights
Investment Highlights Avenova is established in the $4 billion U.S. dry eye market with differentiated positioning and multiple product-specific features and benefits Avenova is the only commercial hypochlorous acid (HOCI) spray clinically proven to treat the underlying cause rather than the symptom
Slide 5: Patented HOCl Formulation is a Platform Technology
Patented HOCI Formulation is a Platform Technology CREP AVENOVA AND CELLERX ARE ALL FORMULATED WITH NOVABAY’S PURE HOCI, WHICH IS FDA 510(K) CLEARED Natural molecule is part of the body’s innate immune system * Effective against all types of pathogens, including a wide variety of viruses such as cor
Slide 6: Avenova Market Opportunity
Avenova Market Opportunity U.S. POPULATION WITH EYE BACTERIA CONCERNS Bacterial Dry Eye is the Most Common Form * Bacterial dry eye (meibomian gland dysfunction and blepharitis) represents 86% of dry eye patients * Aqueous deficient dry eye, treated by Restasis and Xiidra, represent ONLY about 14% 2
Slide 7: Avenova Advantages
Avenova Advantages Clinical study confirms Avenova’s ability = to reduce bacteria on ocular surface by for evenplay sc >90%, not merely treat the symptoms PURE HYPOCHLOROUS ACID, 0.01% Kills >20 microorganisms connected to common eye infections within seconds; effective against a range of pathogens
Slide 8: Direct-to-Consumer Strategy
Direct-to-Consumer Strategy ¢ Accounts for more than three-quarters of Avenova revenue ¢ Provides easy access to Avenova without a prescription or leaving home AVE N OVA’ ¢ Helps to offset the impact of high-deductible healthcare plans ANEMIA LOMY ¢ Provides NovaBay with stable gross-to-net pricing
Slide 9: Refreshed Consumer Lifestyle Branding
Refreshed Consumer Lifestyle Branding purely YW. AVENOVA AAA ORR. woo Sh\ - a ” - ~SEE
Slide 10: Avenova Prescription Sales Channels
Avenova Prescription Sales Channels ¢ Rx Sales/Prescription Channel * The sales organization continues to focus on underserved Retail territories with high-prescribing ophthalmologists and . favorable health plan coverage Pharmacies * Avenova is available in virtually all U.S. retail pharmacies ¢ Sp
Slide 11: Physician testimonial on Avenova
• • • • “Avenova has been a large part of my practice for the past few years. I prescribe it to most of my dry eye, blepharitis and meibomian gland dysfunction patients. I have studied • the effectiveness of this pure form of hypochlorous acid against many bacteria and even viruses and am convinced
Slide 12: CelleRx Clinical Reset
CelleRx Clinical Reset Launched 4Q’20 Direct-to-Consumer in the Beauty Market Clinical Resetisa Gentle, Calming and Soothing Daily Facial Mist CELLERX® AES RE, Oar
Slide 13: CelleRx Clinical Reset | A New Category in Beauty Products
CelleRx Clinical Reset | A New Category in Beauty Products FDA-cleared skincare product proven to help clean and reduce bacteria buildup on facial skin Removes barriers to cell regeneration through gentle olealene and biofilm disruption, without stripping e skin Complementary to a daily beauty regim
Slide 14: CelleRx Clinical Reset — Social Media Marketing
CelleRx Clinical Reset — Social Media Marketing @®CELLERXSKIN SOCIAL MEDIA PRESENCE FOR BEAUTY AND SKIN MARKET DAILY POSTING AND STORIES LIFESTYLE IMAGES AND CONTENT PRESCRIPTION GRADE SKINCARE CELLERX® ee ee ea eT ar.) ee a, |e ee ee ————— —
Slide 15: CelleRx Clinical Reset Consumer Strategy
CelleRx Clinical Reset Consumer Strategy * Leveraging new consumer-focused messaging and NovaBay’s pharmaceutical pedigree in robust social media and print advertising campaigns marketing in the beauty CelleRx® harnes industry the same molecul your body naturally produces. to protect * Debuting with
Slide 16: Leadership
Leadership JUSTIN M. HALL, ESQ CEO, General Counsel & Director Extensive knowledge of NovaBay, having joined in 2013 and serving as CEO since 2019 Lead successful restructuring, implemented direct-to-consumer strategy and leading consumer launch of CelleRx Extensive legal background on wide range of
Slide 17: Strategy for Growth
Strategy for Growth a * Driving Avenova and CelleRx Clinical Reset sales to consumers ¢ DTC channel presents the greatest opportunity for growth * Enhanced e-commerce, digital marketing and advertising programs, and refreshed branding * Expanded online access and new brick-and-mortar availability *
Slide 18: Financial and Operating Highlights
Financial and Operating Highlights a Sa. ee Ge a. ee . ere * Avenova OTC sales top $1 million for the first time on record unit sales in first quarter of 2021 ¢ Sales growth anticipated from refreshed digital advertising campaigns, newly launched products and growing inside sales team ¢ Strong balan
Slide 19: In Summary
In Summary Avenova is established in the $4 billion U.S. dry eye market with differentiated positioning and multiple product-specific features and benefits Avenova is the only commercial hypochlorous acid (HOCI) spray clinically proven to treat the underlying cause rather than the symptoms of bacter
NovaBay Pharmaceuticals — Investor Presentation (June 2021) on 6ix